Kummerfeld Keith C 4
4 · Arcturus Therapeutics Holdings Inc. · Filed Apr 19, 2023
Insider Transaction Report
Form 4
Kummerfeld Keith C
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2023-04-18$4.99/sh+1,437$7,171→ 7,918 total - Sale
Common Stock
2023-04-18$28.18/sh−6,968$196,358→ 950 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-04-17−1,031→ 8,969 totalExercise: $14.12Exp: 2030-02-18→ Common Stock (1,031 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2023-04-17−4,500→ 25,500 totalExercise: $9.04Exp: 2028-07-04→ Common Stock (4,500 underlying) - Exercise/Conversion
Common Stock
2023-04-18$9.04/sh+4,500$40,680→ 6,481 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-04-17−1,437→ 8,563 totalExercise: $4.99Exp: 2029-02-06→ Common Stock (1,437 underlying) - Exercise/Conversion
Common Stock
2023-04-18$14.12/sh+1,031$14,558→ 1,981 total
Footnotes (3)
- [F1]Represents shares sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.62 to $28.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it at each separate price on April 17, 2023.
- [F3]25% of the shares underlying the options vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.